Introduction
The chemokines RANTES (regulated on activation normal T-cell expressed and secreted; CCL5) and platelet factor 4 (PF4; CXCL4) are both released from thegranules of activated platelets. 1 Chemokines are known to govern multiple biological processes and are classified into CXC-chemokines (e.g. PF4) and CC-chemokines (e.g.
RANTES)
according to the position of N-terminal cysteine residues. PF4 exerts chemotactic activities on fibroblasts, neutrophils and monocytes, 2,3 inhibits angiogenesis and proliferation of hematopoietic progenitor cells, [4] [5] [6] promotes adhesion of neutrophils on endothelial cells 3 and supports adhesion of hematopoietic progenitor cells under static conditions 7 . Since the latter effect was not observed after exposure to chondroitinase ABC it may not be mediated by a classical high affinity seventransmembrane domain chemokine receptor. 7 While a specific heptahelical receptor with high affinity for PF4 has been elusive, some functions of PF4 have recently been explained by binding to an alternatively spliced form of the receptor CXCR3 which has been found to be expressed on endothelial cells (ECs). 8 The capability to induce adhesion and transmigration of monocytes and T-cells is a well established feature of RANTES. [9] [10] [11] For instance, both diffusible and anchored forms of RANTES have been found to regulate T cell adhesion to subendothelial extracellular matrix. 12 Moreover, recombinant or platelet-derived RANTES can bind to the surface of activated endothelium, where it triggers the firm arrest and transmigration of monocytes under flow conditions 11, 13 by engaging its receptors CCR1 and CCR5, respectively. [14] [15] [16] These properties of RANTES may be instrumental for its involvement in atherogenic processes, such as neointima formation after arterial injury. 17 In addition, only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From both RANTES and PF4 deposited by circulating platelets, have been implicated in the development of atherosclerotic lesions in apolipoprotein E-deficient mice. 18 Like most chemokines, RANTES and PF4 bind glycosaminoglycans (GAGs) such as heparin, chondroitin sulfate and dermatan sulfate. 19, 20 Mutations of the BBXB motif in RANTES result in profoundly impaired binding to heparin and decreased CCR1 activating capacity, thus identifying a principal site for GAG binding and control of receptor selectivity 20, 21 . In addition, alterations in this motif have been shown to significantly attenuate RANTES aggregation. 21 The propensity to form large aggregates (>200 kD) is an essential feature of RANTES contributing to its recruitment function in vivo. 22 It is noteworthy in this respect that the tetrameric RANTES mutant E26A retains in vivo activity, indicating a minimal structural requirement for proper function.
22
PF4 has been found to interact with other heparin-binding molecules such as basic fibroblast growth factor-2 (bFGF2), vascular endothelial growth factor (VEGF),
antithrombin, protein C and interleukin-8 (IL-8). 7, [23] [24] [25] [26] [27] The interaction of PF4 and IL-8 has been well characterized and is likely to account for the inhibition of IL-8 signaling by PF4 in hematopoietic progenitor cells. 7 However, the precise mechanism and functional consequences of this effect have not been fully elucidated.
Unlike IL-8, RANTES and PF4 are both abundantly stored in -granules and secreted upon stimulation of platelets and thus have ample possibilities for interaction.
Hence, we were prompted to study the combined effects of PF4 and RANTES in modulating adhesion of monocytes and the underlying mechanisms.
only.
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Materials and Methods

Cells and reagents
Human umbilical vein endothelial cells (HUVECs) and growth media were purchased from PromoCell (Heidelberg, Germany) and monocytic Mono Mac 6 (MM6) cells were cultured as described. 28 Monocytes were isolated from buffy coats of heathy donors by hyperosmotic NycoPrep 1.068 density gradient centrifucation. 28 Platelets were isolated from healthy young donors without medication by differential centrifugation to a final concentration to 10 12 /L. Plasma was removed by washing platelets twice in Krebs Ringer (4 mM KCl, 100 mM NaCl, 20 mM NaHCO 3 , 2 mM Na 2 SO 4 , 4.7 mM citric acid, 14.2 mM sodium citrate, pH 5), and platelets were activated with human thrombin (1 U/mL) in
Hank's balanced salt solution, 10 mM Hepes, 0.5% BSA, pH7.4 (HH) for 10 minutes at 37°C. After centrifugation, supernatants were sterile filtered and incubated with MM6 cells for 5 minutes at 37°C. Human RANTES and mutants were prepared as described 20, 22 or were purchased from Peprotech (Rocky Hill, NJ). Platelet-purified human PF4 was obtained from ChromaTec (Greifswald, Germany). Unless stated, reagents were from Sigma-Aldrich (St. Louis, MO).
Laminar flow assay
Laminar flow assays were performed as described. 29 
Ligand Blot
Three µg of each chemokine were applied onto a Hybond ECL nitrocellulose membrane (Amersham, Freiburg, Germany) and dried at room temperature. After blocking the membrane with 5% non-fat milk in Tris-buffered saline (TBS) (150 mM NaCl, 25 mM TrisCl, pH 7.5) for 30 minutes, PF4 (1 µg/mL) binding reactions were performed in the same buffer with 0.05% Tween20 added. After extensive washing with TBS, membranes were only.
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Surface Plasmon Resonance analysis.
RANTES showed high non-specific binding to the carboxymethylated dextran matrix of commonly used CM5 sensorchips. Therefore, a C1 sensorchip without dextran (Biacore AB, Sweden) was treated essentially as described. 21 Two flowcells of a C1 chip were 
Statistical analysis
Data were presented as mean±SEM of at least three independent experiments, and analyzed using GraphPad Prism (GraphPad software, San Diego, CA). Statistical analysis was performed by one-way ANOVA with Newman-Keuls correction for multiple comparison. Differences with P values <0.05 were considered as statistically significant. 
Results
Arrest of MM6 after stimulation with chemokines
Monocyte arrest on endothelium can be triggered by chemokines including GRO-, IL-8 and RANTES 11, 28, 31 . To determine the functional consequences of a recently described interaction of IL-8 with PF4, 7 we performed adhesion assays on activated HUVECs in a parallel wall flow chamber under flow conditions. Stimulation of monocytic MM6 cells with PF4 alone did not increase their arrest, whereas stimulation with IL-8 increased firm monocyte arrest by more than 50% (Fig. 1A ). In line with the abrogation of IL-8 signaling by PF4, 7 the addition of PF4 completely suppressed IL-8-triggered monocyte arrest ( resulted in a two-fold enhancement of RANTES-triggered monocyte arrest (Fig. 1A) .
The amplification of RANTES-triggered arrest was even more pronounced in isolated human blood monocytes where at submaximal concentrations only the combination of RANTES with PF4 significantly increased arrest on activated HUVECs (Fig. 1B) .
To assess whether this effect was dependent on GAGs on the monocyte surface, GAG-degrading enzymes were used. As seen by flow cytometry, MM6 cells expressed chondroitin sulfate as a candidate for surface immobilization of chemokines (not shown).
Accordingly, pretreatment of MM6 cells with chondroitinase ABC significantly reduced arrest triggered by RANTES alone or by the combination of PF4 and RANTES (Fig. 1C) , whereas heparinase I and III had no significant effect (data not shown). This indicates a predominant requirement for chondroitin sulfate in RANTES-induced monocyte arrest.
Increased surface binding of PF4 after coincubation with RANTES
To explore whether enhanced monocyte arrest may be related to direct interactions of PF4 and RANTES, PF4 bound to the cell surface was analyzed by flow cytometry. Preincubation with a combination of RANTES and PF4 resulted in increased binding of PF4 to MM6 cells ( Fig. 2A-D) , possibly attributable to a modulation of PF4 binding affinities or to an availability of additional binding sites following hetero-oligomerization. These results were reproducible with formaldehyde-fixed MM6 cells (not shown), excluding RANTES-induced PF4 secretion or an upregulation of PF4 binding sites as underlying mechanisms. Pretreatment with chondroitinase ABC inhibited the binding of PF4 to the monocyte surface, indicating that it was mediated by chondroitin sulfate (Fig. 2D) .
Solid phase detection of RANTES/PF4 interaction
To obtain further evidence for an interaction of PF4 and RANTES, ligand blots were performed. In agreement with findings that PF4 binds IL-8 with high affinity, 7 we observed binding of PF4 to immobilized IL-8 (Fig. 3A) . Notably, we were also able to detect binding of PF4 to immobilized wild-type RANTES. To identify structural properties responsible for the interaction of RANTES with PF4, we employed different variants of RANTES, which are defective in higher order oligomerization. Synthetic RANTES T is N-methylated at threonine-7 and has been shown to exist strictly as monomer. (Fig. 3) . In order to confirm these results, the interaction between RANTES only.
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and PF4 was investigated using surface plasmon resonance. In agreement with the ligand blot (Fig 3A) , wild-type RANTES bound to synthetic biotinylated PF4 (Fig. 3B ). In addition, tetrameric E26A RANTES also bound to bPF4 albeit with lower affinity (Fig   3B,C) , while monomeric Nme- 7 T RANTES and 44 
AANA
47 RANTES did not bind to bPF4 (Fig 3C) . RANTES showed considerable background binding (up to 50% of the specific signal) and displayed complex binding behaviour. This, in conjunction with the inherent heterogeneity of RANTES, prevented a quantitative kinetic analysis for the interaction between RANTES and PF4. Apparent equilibrium dissociation constants were derived for the interaction between PF4 with RANTES or E26A RANTES from equilibrium binding measurements using non-linear regression and were found to be 0.8 µM and 3.8
µM, respectively. These data suggest that the same residues of RANTES involved in either oligomerization or binding to GAGs may also be a prerequisite for the heterotypic interaction with PF4.
Functional interactions with PF4 are not supported by E26A RANTES
Since the RANTES variants employed may not only differ in their binding to PF4 but also in their binding to GAGs, 20, 22 we studied cell surface binding following preincubation of T-variant were hardly detectable on the monocyte surface (Fig. 4) . In contrast, E26A RANTES and wild-type RANTES showed robust and equivalent binding to monocytic cells (Fig. 4) .
Because E26A RANTES was the only mutant exhibiting impaired heterophilic interactions with PF4 and at the same time preserved surface binding to monocytic cells, we next tested whether it also affects surface binding of PF4, as seen in Fig. 2B and whether it allows enhancement of arrest by PF4. In contrast to coincubation with wildonly.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From type RANTES, however, a significant increase in PF4 surface binding was not observed after combination with E26A RANTES (Fig. 5A ). In line with previous findings, 33 E26A RANTES was immobilized on HUVECs (data not shown) and retained an ability to trigger monocyte arrest under flow conditions almost equivalent to that of wild-type RANTES (Fig. 5B) . Pretreatment with chondroitinase ABC confirmed that PF4 binding and E26A-triggered arrest involved chondroitin sulfate (Fig. 5A,B) . In contrast to the combination of wild-type RANTES and PF4, the combination of E26A RANTES with PF4
failed to further enhance monocyte arrest (Fig 5B) . Thus, the heterophilic interaction with PF4, which is attenuated by mutation of the E26 residue in RANTES, is required for the functional enhancement of RANTES-mediated arrest by PF4. This clearly indicates that a direct interaction of RANTES and PF4 is necessary for increased arrest.
PF4 and RANTES from activated platelets
Finally, we tested whether the effects of platelet supernatants on monocyte arrest are attributable to the mechanisms defined for recombinant RANTES and PF4 herein. In line with findings that RANTES and PF4 released from activated platelets may bind to the monocyte surface, 18 flow cytometric analysis revealed that the incubation of MM6 cells with supernatants of thrombin-activated platelets resulted in a marked increase in surface binding of both PF4 and RANTES (Fig. 6A-D) . The stimulation of monocytic cells with supernatants of activated platelets further resulted in a significant enhancement of their arrest on activated HUVECs in flow, which was blocked by pretreatment with Met-RANTES and partially reduced with polyclonal antibodies against PF4 (Fig. 6E) 35 Moreover, treatment with heparitinase inhibited monocyte arrest mediated by GRO-on activated HUVECs. 28 Similarly, the presence of chondroitin sulfate appeared to be crucial for the synergistic effect on monocyte arrest stimulated by the combination of RANTES and PF4, as revealed by enzymatic cleavage with chondroitinase ABC. Although both RANTES and PF4 bind to heparin as well as other GAGs, heparinase treatment did not significantly affect this increase in monocyte arrest.
Thus, GAGs may form a highly specific substrate on cell surfaces which allows selective chemokine presentation and subsequent activation of their cognate receptors.
Several mechanisms, which may not be mutually exclusive, can be proposed to provide an explanation for the increased arrest triggered by the combination of PF4 and RANTES. Firstly, PF4 may form hetero-oligomers with RANTES, which may promote binding of RANTES to GAGs on monocytes by recruiting additional binding sites or by altering affinity to enhance chemokine-receptor-activation. In turn, the presence of only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From RANTES may increase the binding of PF4 to the monocyte surface by conformational changes enhancing the affinity of PF4 for GAGs. This may be due to a distinctive interface formed by the hetero-oligomer, which may bind to both RANTES-specific and PF4-specific GAGs. Given the moderate affinity of RANTES to PF4 (apparent K d =0.8 µM) specific GAG substrates may further facilitate the interaction of RANTES and PF4 owing to mechanisms resembling cooperativity. Notably, the E26A RANTES mutant, which has impaired higher order oligomerization and PF4 interaction, but retains affinity for heparin and cell surface binding, did not increase binding of PF4 to monocytes, suggesting an important role for this residue in hetero-oligomerization and its functional consequences. Alternatively, higher order oligomerization of RANTES may be a prerequisite for the interaction with PF4. Although the tetrameric structure of E26A RANTES appeared to retain a limited capacity for interaction with PF4 (apparent K d =3.8 µM), the low affinity of this interaction may not be sufficient to support RANTES functions. Importantly, monocyte arrest triggered by E26A RANTES was not influenced by PF4, implying that higher order hetero-oligomerization plays a key role in the enhancement of monocyte arrest by PF4.
Secondly, chemokine complexes composed of PF4 and RANTES may induce or stabilize heterodimerizaton of chemokine receptors resulting in different signaling events. Similar to other receptors (e.g. CCR2 and CXCR4) undergoing ligand-induced heterodimerization, CCR5 oligomers are present in unstimulated cells and RANTES induces and stabilizes the oligomeric conformation with the highest binding affinity. [36] [37] [38] [39] Conversely, the monomeric conformation of CCR5 is an inactive receptor state, unable to trigger cell functions or to activate the JAK-STAT-pathway. Moreover, CCR5 has only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From been shown to heterodimerize with CCR2, and the resulting receptor complex activates signaling events distinct from those triggered by the homodimers. 40 Thirdly, PF4 might induce intracellular signaling, leading to enhanced RANTESdependent effects. Neither PF4 nor TNF-alone but their combination induces a relevant exocytotic response by neutrophils, suggesting the participation of more than one signaling pathway controlling this process. 41 Indeed, neutrophil exocytosis induced by PF4 and TNF-is regulated by at least three different signaling elements: p38 MAP kinase, PI 3-kinase, and Lyn src-kinase. 42 Similar to TNF-, RANTES is able to activate the p38 MAP kinase pathway in monocytes via CCR5, 43, 44 indicating the possibility of an analogous signaling mechanism for the co-stimulatory effect of RANTES and PF4.
The latter considerations may also be important for the abrogation of IL-8
signaling by PF4 in CD34+ progenitors, which is unlikely due to direct competition of PF4 for the IL-8 receptors CXCR1 or CXCR2, because PF4 does neither displace IL-8 bound to neutrophils 41 nor down-regulate CXCR1/CXCR2 expression. 45 The effect may rather be attributable to an activation of CXCR3b or a different specific high-affinity CXC-receptor which may generate an intracellular signal that, in turn, blocks downstream IL-8 signaling. Such mechanisms are supported by findings that PF4 blocks bFGF2-dependent phosphorylation of external signal-regulated kinase (ERK) but not AKT in ECs at concentrations that do not impair FGF2 binding to its receptors. 34 Contrary functional effects of PF4 at different concentrations 5 modulating the activity of IL-8 highlight the relevance for oligomerization for the activity of chemokines.
At concentrations of 0.1-1 ng/mL PF4 occurs predominantly as a monomer 46 Activation of platelets leads to secretion of proinflammatory mediators and chemokines and plays a crucial role in inflammatory diseases, atherosclerosis and neointima formation. 17, 18, 47, 48 Both RANTES and PF4 are released from -granules upon platelet-stimulation and can be deposited on inflamed or atherosclerotic endothelium and monocytes. 18 Low concentrations (< 1nM) of PF4 and RANTES have been detected in human plasma. However, a 100-1000 fold increase in their concentrations has been observed after platelet activation. 11, 49 As both chemokines are stored in the same compartment the formation of heteroaggregates is likely to also occur in vivo. Our results show that both chemokines bind to the surface of monocytes and are involved in mediating increased monocyte arrest on inflamed endothelium following platelet preperfusion. Given that PF4 alone does not affect arrest, these data indicate that the amplifying mechanism by PF4 is also operative following platelet activation and the release of multiple platelet-derived mediators and consequently in promoting atherogenic recruitment of monocytes.
Taken together, our findings support the notion that hetero-aggregates of PF4
and RANTES crucially contributes to the surface binding and the concerted activity of platelet-derived chemokines, in triggering monocyte recruitment in inflammation or atherosclerosis.
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